Pharmaceutical professional with over 25 years of experience in academia, industry, and the government (U.S. FDA). He has experience working in US, and India and has experience developing products for worldwide markets and an established network of partners globally. He currently oversees all the development, and project management and acts as the CEO of the company.

A highly revered professional with several decades of experience in academia and industrial pharmaceutical research. He was previously serving as Vice President, Clinical Development at Mallinckrodt where he spent several years providing leadership in the areas of Clinical Pharmacology and Clinical Development. He played a very critical role in the approval of several products. He is the brain behind the scientific and clinical development strategies at 6S and leads 6S’ ideation efforts and currently is our CSO.

Dr. Devarakonda is the director of Thoracic Medical Oncology at Swedish Cancer Institute (SCI), Seattle, WA. He is board certified in Medical Oncology. He  completed his training from Washington University (Wash U.) School of Medicine in St. Louis and worked as an Associate Professor at Wash U before moving to SCI in 2023. He has the experience of serving as a Principal Investigator on several industry sponsored and investigator-initiated clinical trials. He has a particular interest in phase I/first-in-human trials. He is a translational researcher with an interest in cancer genomics, and has worked with consortia such as at TCGA and LACE-Bio II. He has several research publications to his credit. He maintains an active role at several professional organizations like ASCO, IASLC and ITMIG. He has appeared in numerous interviews and is regarded as a key opinion leader in Thoracic Oncology. 

He is our primary advisor on all our oncology and oncology supportive treatment programs.